IRL790C005: A Randomized, Double-Blind, Placebo-Controlled, Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily ON-Time Without Troublesome Dyskinesia in Patients with Parkinson#s Disease

Grants and Contracts Details

StatusFinished
Effective start/end date5/27/212/28/23

Funding

  • Integrative Research Laboratories Sweden AB: $28,884.00